Your browser doesn't support javascript.
loading
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Bodemer, C; Kaszuba, A; Kingo, K; Tsianakas, A; Morita, A; Rivas, E; Papanastasiou, P; Keefe, D; Patekar, M; Charef, P; Zhang, L; Cafoncelli, S; Papavassilis, C.
Afiliação
  • Bodemer C; Department of Dermatology, Hôpital Necker-Enfants Malades, APHP, Paris, France.
  • Kaszuba A; DERMED Medical Services, Lodz, Poland.
  • Kingo K; Tartu University Hospital and University of Tartu, Tartu, Estonia.
  • Tsianakas A; Fachklinik Bad Bentheim, Bad Bentheim, Germany.
  • Morita A; Nagoya City University Hospital, Aichi, Japan.
  • Rivas E; Dermos, Guatemala City, Guatemala.
  • Papanastasiou P; Novartis Pharma AG, Basel, Switzerland.
  • Keefe D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Patekar M; Novartis Pharma AG, Basel, Switzerland.
  • Charef P; Novartis Pharma AG, Basel, Switzerland.
  • Zhang L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Cafoncelli S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
J Eur Acad Dermatol Venereol ; 35(4): 938-947, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33068444
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article